XBiotech Inc.: FDA Gives Go-Ahead for XBiotech's Candidate Therapy for Phase I/II Double-blind Placebo Controlled Study in Pancreatic Cancer
(1) XBiotech's New Drug to Enter Clinical Studies in Combination Therapy for Pancreatic Cancer AUSTIN, Texas, April 19, 2021 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced today that the FDA has granted permission to commence clinical trials with its novel drug candidate for treating patients with pancreatic cancer. From 1992 to 2018 the death rate from pancreatic cancer steadily increased in the USA. It is now predicted that pancreatic cancer will claim 48,220 lives and be the 3 rd leading cause of cancer death in the USA in 2021 (National Cancer Institute's Surveillance, Epidemiology...
Source: finanznachrichten.de